A detailed history of Caption Management, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Caption Management, LLC holds 30,000 shares of RCUS stock, worth $473,100. This represents 0.01% of its overall portfolio holdings.

Number of Shares
30,000
Previous 49,300 39.15%
Holding current value
$473,100
Previous $750,000 38.93%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $14,590 - $18,480
1,000 Added 20.0%
6,000 $91,000
Q1 2024

May 15, 2024

SELL
$14.83 - $20.18 $220,967 - $300,682
-14,900 Reduced 74.87%
5,000 $94,000
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $159,817 - $233,597
11,900 Added 148.75%
19,900 $380,000
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $140,960 - $188,320
8,000 New
8,000 $143,000
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $143,640 - $208,350
9,000 New
9,000 $164,000
Q1 2022

May 13, 2022

BUY
$28.92 - $41.83 $628,720 - $909,384
21,740 New
21,740 $686,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.